Organon, Philips to study drug effects at molecular level
Organon, the human healthcare business unit of Akzo Nobel, and Royal Philips Electronics are partnering to development new drugs and therapies for mental disorders and cancer. They will do so with the aid of biomarkers and Philips' non-invasive medical imaging technology. The collaboration will provide examples of how the impact of psychiatric drugs can be witnessed in the brain at the molecular level.
Molecular imaging can speed up the development and approval of new drugs and therapies by measuring drug effects at the molecular level. Imaging technologies can be used to monitor the effect of the therapy and customize the treatment program accordingly. Such customized treatment programs could accelerate and improve patient outcomes.
"Organon has invested heavily in optimizing its R&D efforts," said David Nicholson, executive vice president, research and development, Organon. "We are convinced that biomarker research will accelerate the R&D process and improve the success rate of developing new molecular and biological therapies. In particular, our drug development programs for the treatment of psychiatric and immune disorders are expected to benefit from this collaborative research effort with Philips."
Scientists from Organon will work at the Philips Life Sciences Facilities situated at the High Tech Campus in Eindhoven, the Netherlands. The multi-disciplinary research facility provides the necessary biological, chemical and technical infrastructure and expertise for research and development in the field of translational biomarkers and molecular medicine.
Philips’ medical imaging modalities have evolved to the point that they are now effective tools in imaging “the function and behavior of an anatomical feature, and not just its shape," said Rick Harwig, CTO, Philips. "The combined technological expertise of Philips and the life sciences know-how of Organon will definitely speed up the evolution of our imaging modalities into tools to image the body at the molecular level. In addition, they will enable new opportunities in molecular diagnostics."
Molecular imaging can speed up the development and approval of new drugs and therapies by measuring drug effects at the molecular level. Imaging technologies can be used to monitor the effect of the therapy and customize the treatment program accordingly. Such customized treatment programs could accelerate and improve patient outcomes.
"Organon has invested heavily in optimizing its R&D efforts," said David Nicholson, executive vice president, research and development, Organon. "We are convinced that biomarker research will accelerate the R&D process and improve the success rate of developing new molecular and biological therapies. In particular, our drug development programs for the treatment of psychiatric and immune disorders are expected to benefit from this collaborative research effort with Philips."
Scientists from Organon will work at the Philips Life Sciences Facilities situated at the High Tech Campus in Eindhoven, the Netherlands. The multi-disciplinary research facility provides the necessary biological, chemical and technical infrastructure and expertise for research and development in the field of translational biomarkers and molecular medicine.
Philips’ medical imaging modalities have evolved to the point that they are now effective tools in imaging “the function and behavior of an anatomical feature, and not just its shape," said Rick Harwig, CTO, Philips. "The combined technological expertise of Philips and the life sciences know-how of Organon will definitely speed up the evolution of our imaging modalities into tools to image the body at the molecular level. In addition, they will enable new opportunities in molecular diagnostics."